24 month-treatment with miglustat of three patients with Niemann-Pick disease type C: follow up using brain spectroscopy. - Wikidata - awgldk - TriplyDB

24 month-treatment with miglustat of three patients with Niemann-Pick disease type C: follow up using brain spectroscopy.

24 month-treatment with miglustat of three patients with Niemann-Pick disease type C: follow up using brain spectroscopy.

http://www.wikidata.org/entity/Q34600390

about

Niemann-Pick disease type C Niemann-Pick disease treatment: a systematic review of clinical trials Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustat Niemann-Pick disease type C symptomatology: an expert-based clinical description Recent advances in the diagnosis and treatment of niemann-pick disease type C in children: a guide to early diagnosis for the general pediatrician Miglustat: a review of its use in Niemann-Pick disease type C.Multi-system disorders of glycosphingolipid and ganglioside metabolism Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrin Size and shape of the corpus callosum in adult Niemann-Pick type C reflects state and trait illness variables.Niemann-Pick type C pathogenesis and treatment: from statins to sugars.Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type C.Oxidative stress: a pathogenic mechanism for Niemann-Pick type C disease.Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C.Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in niemann-pick type C.(1) H magnetic resonance spectroscopy of neurodegeneration in a mouse model of niemann-pick type C1 disease.Normalisation of brain spectroscopy findings in Niemann-Pick disease type C patients treated with miglustat.New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat Treatable metabolic psychoses that go undetected: what Niemann-Pick type C can teach us.Extracellular matrix components: an intricate network of possible biomarkers for lysosomal storage disorders?Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies.Niemann-Pick type C: focus on the adolescent/adult onset form.Impact of miglustat on evolution of atypical presentation of late-infantile-onset Niemann-Pick disease type C with early cognitive impairment, behavioral dysfunction, epilepsy, ophthalmoplegia, and cerebellar involvement: a case report.Longitudinal changes in cerebellar and subcortical volumes in adult-onset Niemann-Pick disease type C patients treated with miglustat.In Vivo Assessment of Neurodegeneration in Type C Niemann-Pick Disease by IDEAL-IQ.Heterogeneity and frequency of movement disorders in juvenile and adult-onset Niemann-Pick C disease.The extending spectrum of NPC1-related human disorders: from Niemann-Pick C1 Disease to obesity.Consensus clinical management guidelines for Niemann-Pick disease type C.Recent neuroimaging, neurophysiological, and neuropathological advances for the understanding of NPC.Miglustat in Niemann-Pick disease type C patients: a review

P2860

Q21202883-9274F752-FA8F-40D1-B60D-6F8B56BBC7BC Q26774861-C1FFAEC9-E2D7-41C7-939D-1FCCEC1AC9BB Q26825102-4C5DEC8F-A0CA-45C0-80E6-8AFA186A66C2 Q26860273-71C6A7F8-561F-4DAE-9BC6-E03835287F41 Q28082532-C21CE74C-5F46-4688-AA8A-4347CF5103A7 Q33460275-4113EBDB-728B-4A8C-B094-4350F2297F2E Q33902037-72657363-CC02-414B-9A3C-298B86AC49E2 Q33945068-62E31F18-CF42-49EA-BFE5-90FF9F7452E9 Q34186279-C96227A1-604D-4CF3-920C-558D47A57407 Q34632493-6B8DF809-E18F-4133-8FF3-6094FC76194D Q35960437-F6273D43-42C7-4275-B884-8559785A0842 Q36031149-D7218730-1F39-44BA-9E92-A8F91173129E Q36299871-BE8717D3-AC16-4763-8A3E-DEF64CEBF714 Q36433310-CDF697D8-8663-4078-A70D-BE4BBF5BE8ED Q36838600-62504662-2558-4B9B-B103-D4A15CE5794E Q36879362-A423F861-3EF5-421D-9BF2-6484181A4B4D Q37429819-1C45410A-AE69-4E3D-8B7B-79B88F063ABE Q38022679-FF6538B4-98B9-49C2-8D1F-75EC95479382 Q38085972-16018AD0-7B6A-4391-A2A6-52920EDA5010 Q38598049-4282D7C4-187A-4843-A423-3167FA5806BC Q38783095-4EDFDBF0-DD2D-4FB6-8E64-75D645AE5257 Q39418392-60C8A856-60F1-4E35-8574-B0D4F91248B1 Q40818505-2277192C-0145-4E59-A157-867D1C38DEFA Q47707804-98C79ADE-ECF8-4020-8EA0-745A542E51BA Q48901340-B6826A49-2D65-495F-9299-6F2A048F2BDE Q50084571-D54CABF7-AC31-4654-9EA3-E897A565D355 Q52602028-6EE95A7E-48D5-4DAE-80CB-D3BD3E63980C Q52670912-B9D3405A-521D-4283-BDEB-1F94A57EBE94 Q58778074-F86A4DF6-5A9B-4F1A-AB22-6D31471F04D5

P2860

24 month-treatment with miglustat of three patients with Niemann-Pick disease type C: follow up using brain spectroscopy.

http://www.wikidata.org/entity/Q34600390

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

24 month-treatment with miglus ...... w up using brain spectroscopy.

@ast

24 month-treatment with miglus ...... w up using brain spectroscopy.

@en

24 month-treatment with miglus ...... w up using brain spectroscopy.

@nl

type

label

24 month-treatment with miglus ...... w up using brain spectroscopy.

@ast

24 month-treatment with miglus ...... w up using brain spectroscopy.

@en

24 month-treatment with miglus ...... w up using brain spectroscopy.

@nl

prefLabel

24 month-treatment with miglus ...... w up using brain spectroscopy.

@ast

24 month-treatment with miglus ...... w up using brain spectroscopy.

@en

24 month-treatment with miglus ...... w up using brain spectroscopy.

@nl

P1433

Q34600390-256071B7-4A11-4081-8F5D-BDE1B409400E

P1476

Q34600390-1A955F95-D94C-497A-B3A8-E81263285ED9

P2093

Q34600390-17DD351F-6B3E-4872-8A8E-48A2154D75B1

Q34600390-3A05D028-FA69-408F-A741-3D941AC85D0A

Q34600390-4BE12616-82A8-49E4-A2D4-462D35734840

Q34600390-5ACD1C5E-1893-41FC-9F65-CD5F7D273207

Q34600390-BF4A47D6-0959-40A0-9106-1F3E4A6567C9

Q34600390-CE0DB66D-BCA8-463B-9462-17FE8030D5BB

Q34600390-E1C32306-6623-46BF-A77F-53EF69C5775E

Q34600390-E2DC451A-4D6C-4751-A3E1-4220CEA5BB8B

Q34600390-FE014F68-FCC6-49DA-9574-E7A46D8322DC

Q34600390-FF721848-5937-4B04-9354-D3A425EB8591

P304

Q34600390-976DCF60-1AA6-41A0-A0E3-9ED31F5135AE

P31

Q34600390-A8CBCB62-5376-4065-9EB3-2981E521DE51

P356

Q34600390-3C59DEF6-185C-4968-A680-74A54A04F1D0

P433

Q34600390-FE796E16-A24F-4A6A-ADDE-790ADA3F7F93

P478

Q34600390-AB93B9CF-7187-4CBC-AA0B-56BCA3AB2F70

P50

Q34600390-D8927114-065D-478D-B334-F8C6B56B4F60

P577

Q34600390-E3837EF3-E730-4A95-A7F5-29B9291DAA0A

P5875

Q34600390-C3A07059-B8E4-4CBC-933D-5D7CABBD3769

P698

Q34600390-4FEBD98B-217C-402F-AEE2-3962DD2011F3

P356

J.YMGME.2008.10.002

P1433

Molecular Genetics and Metabolism

P1476

24 month-treatment with miglus ...... w up using brain spectroscopy.

@en

P2093

Ayman Tourbah

http://www.w3.org/2001/XMLSchema#string

Bénédicte Heron

http://www.w3.org/2001/XMLSchema#string

Damien Galanaud

http://www.w3.org/2001/XMLSchema#string

François Feillet

http://www.w3.org/2001/XMLSchema#string

Frédéric Sedel

http://www.w3.org/2001/XMLSchema#string

Marie T Vanier

http://www.w3.org/2001/XMLSchema#string

Nathalie Guffon

http://www.w3.org/2001/XMLSchema#string

Nathalie Leveque

http://www.w3.org/2001/XMLSchema#string

Nicole Baumann

http://www.w3.org/2001/XMLSchema#string

Stéphane Lehéricy

http://www.w3.org/2001/XMLSchema#string

P304

55-58

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YMGME.2008.10.002

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P50

Thierry Billette de Villemeur

P577

2008-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

222176262

http://www.w3.org/2001/XMLSchema#string

P698

19013089

http://www.w3.org/2001/XMLSchema#string